Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar

This article was originally published in The Gray Sheet

Executive Summary

The FDA Circulatory System Devices Panel endorsed Boston Scientific's proposed ARRIVE 2,000-patient, five-year Taxus postmarket study with no additional conditions beyond proposals made by the company

You may also be interested in...



Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman

FDA is encouraging PMA sponsors to file a continued-access protocol for a long-term trial that will meet postmarket study requirements following a device's approval

Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman

FDA is encouraging PMA sponsors to file a continued-access protocol for a long-term trial that will meet postmarket study requirements following a device's approval

Cordis Parries Taxus Approval Thrust With REALITY Procedure Success Data

Post-market surveillance of Boston Scientific's Taxus paclitaxel-eluting stent will cover over 3,500 patients and include five-year follow-up on more than 1,500 patients treated in pre-market trials

Related Content

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel